Bio-Path Holdings Provides 2024 Clinical and Operational Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Roth/MKM Reiterates $40 PT on Bio-Path Holdings (BPTH): 'Business Update Includes Developing Prexigebersen For Obesity'
April 2, 2024 10:50 AM EDTRoth/MKM analyst Philip Shen reiterated a Buy rating and $40.00 price target on Bio-Path Holdings (NASDAQ: BPTH).
The analyst comments "BPTH outlined its business plan most notably by adding obesity and obesityrelated cancers to its prexigebersen development plans, a drug currently in Phase 2 development in AML. BPTH is... More
